Literature DB >> 32975104

Cholinergic syndrome: a case report of acute organophosphate and carbamate poisoning.

Tadej Petreski1,2, Barbara Kit3, Matej Strnad2,4, Damjan Grenc5, Franc Svenšek3.   

Abstract

Cholinergic syndrome is a common topic at western medical universities yet rarely observed in clinical practice. The treatment involves muscarinic antagonists, acetylcholinesterase reactivation, seizure control, and supportive measures. Here we report a case of a 52-year old Caucasian male who attempted suicide by ingesting a purple crystal powder that turned out to be a mixture of carbofuran and chlormephos. At clinical examination, the patient presented with salivation, perspiration, diarrhoea, bradypnoea, loss of consciousness, and epileptic seizures. Laboratory tests showed low plasma cholinesterase, and we started obidoxime along with supportive intensive care treatment. He was later transferred to the psychiatry department for further diagnostics and treatment.

Entities:  

Keywords:  carbofuran; chlormephos; critical care; obidoxime

Mesh:

Substances:

Year:  2020        PMID: 32975104      PMCID: PMC7968493          DOI: 10.2478/aiht-2020-71-3413

Source DB:  PubMed          Journal:  Arh Hig Rada Toksikol        ISSN: 0004-1254            Impact factor:   2.078


  12 in total

Review 1.  Antioxidants in organophosphorus compounds poisoning.

Authors:  Syed M Nurulain; Peter Szegi; Kornèlia Tekes; Syed N H Naqvi
Journal:  Arh Hig Rada Toksikol       Date:  2013       Impact factor: 1.948

Review 2.  Management of Organophosphorus Poisoning.

Authors:  S R Bajracharya; P N Prasad; R Ghimire
Journal:  J Nepal Health Res Counc       Date:  2016-09

Review 3.  Neurotoxic effects of organophosphorus pesticides and possible association with neurodegenerative diseases in man: A review.

Authors:  Milan Jokanović
Journal:  Toxicology       Date:  2018-09-25       Impact factor: 4.221

Review 4.  Oxidative stress in organophosphate poisoning: role of standard antidotal therapy.

Authors:  Nela Vanova; Jaroslav Pejchal; David Herman; Alzbeta Dlabkova; Daniel Jun
Journal:  J Appl Toxicol       Date:  2018-03-08       Impact factor: 3.446

Review 5.  Neurotoxicity in acute and repeated organophosphate exposure.

Authors:  Sean X Naughton; Alvin V Terry
Journal:  Toxicology       Date:  2018-08-23       Impact factor: 4.221

Review 6.  Neurosteroids for the potential protection of humans against organophosphate toxicity.

Authors:  Doodipala Samba Reddy
Journal:  Ann N Y Acad Sci       Date:  2016-07-23       Impact factor: 5.691

7.  Investigation of kinetic interactions between approved oximes and human acetylcholinesterase inhibited by pesticide carbamates.

Authors:  Timo Wille; Lisa Kaltenbach; Horst Thiermann; Franz Worek
Journal:  Chem Biol Interact       Date:  2013-08-17       Impact factor: 5.192

Review 8.  Red blood cell acetylcholinesterase and plasma butyrylcholinesterase status: important indicators for the treatment of patients poisoned by organophosphorus compounds.

Authors:  Horst Thiermann; Kai Kehe; Dirk Steinritz; John Mikler; Ira Hill; Thomas Zilker; Peter Eyer; Franz Worek
Journal:  Arh Hig Rada Toksikol       Date:  2007-09       Impact factor: 1.948

Review 9.  Adverse effects of organophosphorus pesticides on the liver: a brief summary of four decades of research.

Authors:  Somayyeh Karami-Mohajeri; Ahmad Ahmadipour; Hamid-Reza Rahimi; Mohammad Abdollahi
Journal:  Arh Hig Rada Toksikol       Date:  2017-12-20       Impact factor: 1.948

10.  PubChem 2019 update: improved access to chemical data.

Authors:  Sunghwan Kim; Jie Chen; Tiejun Cheng; Asta Gindulyte; Jia He; Siqian He; Qingliang Li; Benjamin A Shoemaker; Paul A Thiessen; Bo Yu; Leonid Zaslavsky; Jian Zhang; Evan E Bolton
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  1 in total

1.  Assessment of four organophosphorus pesticides as inhibitors of human acetylcholinesterase and butyrylcholinesterase.

Authors:  Tena Čadež; Dora Kolić; Goran Šinko; Zrinka Kovarik
Journal:  Sci Rep       Date:  2021-11-02       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.